Alis Biosciences to press struggling biotechs during downturn
The horde of zombie biotechs lurching ahead and barely surviving has reached a crisis level for some investors. Now there’s a new investment fund targeting these companies. Nicholas Johnston, a...
View ArticleALX Oncology reports Phase 2 failures for CD47 drug combo with Keytruda
ALX Oncology’s efforts to progress a CD47 combo hit a major speed bump. The company said Friday that two trials testing different combinations of its CD47-targeting drug failed to meet their ...
View ArticleAkeso reveals survival data for Keytruda-beating cancer drug
Akeso Biopharma won first-line approval in China for its lung cancer drug ivonescimab, a new immunotherapy that it believes will top Merck's megablockbuster PD-1 drug. As part of the approval, the...
View ArticleRFK Jr. touts program testing ways to pay for sickle cell care
CHARLESTON, SC — HHS Secretary Robert F. Kennedy Jr. said Friday that 35 states had signed up to participate in a new payment model meant to improve access to and lower costs for gene therapies for ...
View ArticleCompounding pharmacies dealt blow in semaglutide shortage case
Novo Nordisk scored a major win in its wide-ranging legal fight to keep compounders from making copies of its obesity drug semaglutide. A federal district court in Texas on Thursday denied a request...
View ArticleAmgen invests $900M to expand Ohio biomanufacturing
Amgen is the latest in a series of biopharma companies to announce a massive new US-based investment in manufacturing in response to the Trump administration's call to bring pharma manufacturing to the...
View ArticleAbbVie eyes $10B US expansion amid sector-specific tariff threat
AbbVie CEO Rob Michael said the company will invest $10 billion in the US over the next decade, as the threat of pharmaceutical-specific tariffs looms. AbbVie announced plans in its first-quarter...
View ArticleFDA chief Makary talks expediting drug approvals, RIFs and the abortion pill
FDA Commissioner Marty Makary is ramping up his public presence, recently sitting for an interview with Megyn Kelly and participating in an HHS event on removing some dyes from the American food...
View ArticleEarnings season is upon us; Makary on rare disease; Startup is first to...
Welcome back to Endpoints Weekly! Our team of reporters covered first-quarter earnings results from a handful of companies this week. See below for pharma executives’ comments on tariff exposure,...
View ArticleJ&J reports durability data for bladder cancer 'pretzel' drug
Johnson & Johnson said its drug-device combo for bladder cancer achieved a high rate of complete responses lasting at least a year, according to the latest data cut from a registrational trial....
View Article#AACR25: Revolution’s KRAS drug shows potential in early cut of lung cancer data
CHICAGO — An experimental KRAS G12D drug from Revolution Medicines made waves last year as a potential treatment for pancreatic cancer. On Sunday, new results from an early data readout showed it works...
View Article#AACR25: Keytruda around head and neck cancer surgery cuts chance of disease...
CHICAGO — Merck’s widely used cancer drug Keytruda could soon be getting another indication — this time for use before and after surgery for head and neck cancer. On Sunday, data presented from the...
View Article#AACR25: GSK’s checkpoint blocker Jemperli cures biomarker-driven rectal cancer
GSK’s Jemperli has maintained its outstanding efficacy among patients with a particular form of rectal cancer. Every one of 49 patients with mismatch repair deficient (MMRd) rectal tumors in a...
View ArticleExclusive: Axiom raises $15M to build AI models for drug toxicity
Brandon White started his career like a Silicon Valley stereotype. He's a 20-year-old who skipped college to join Uber’s machine-learning team in 2014. But White soon found himself unhappy and...
View ArticleFrance stops Valneva's chikungunya vaccine rollout in over 65s after safety...
France’s national public health agency is suspending immunization of adults 65 years and older with Valneva’s chikungunya vaccine Ixchiq after three patients were hospitalized, including one who died....
View ArticleEuropean regulators recommend new drugs from Vertex, Amgen and Jazz
Vertex Pharmaceuticals, Amgen and Jazz Pharmaceuticals are among companies that received a positive opinion from European regulators for drugs that are already in the US market. The European Medicines...
View ArticleMerck KGaA to buy rare cancer biotech SpringWorks for $3.9B
Merck KGaA said Monday it has inked a “definitive agreement” to acquire Pfizer spinout SpringWorks Therapeutics for an equity value of around $3.9 billion, rounding off several months of negotiations....
View Article#AACR25: Boehringer’s updated results in HER2-mutated lung cancer impress
CHICAGO — Boehringer Ingelheim’s targeted lung cancer drug led to durable responses, according to the latest data from the early-stage trial. The German drugmaker is studying zongertinib in lung cancer...
View ArticleDaiichi Sankyo says production boost in US will help cushion tariff impact
Daiichi Sankyo has reiterated that its earlier plans to expand ADC manufacturing in the US, including for its blockbuster drug Enhertu, will help alleviate some pressure from President Donald Trump's...
View ArticleScholar Rock names new CEO, adds biotech veterans in C-suite rebuild
As it awaits an FDA approval decision, Scholar Rock is reshaping its leadership team with industry veterans. Current CEO Jay Backstrom is departing the Cambridge, MA-based drug developer in a "planned...
View Article
